standard management

Phase 3Small molecule

UUniversity Hospital, Rouen

standard management is one of 101 small molecule programs targeting Pneumonia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

Back PainActive, not recruiting

Colorectal CancerActive, not recruiting

PneumoniaPreclinical

Active, not recruiting

Back PainPreclinical

Active, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

standard management

UUniversity Hospital, Rouen

Phase 3

1 2

Eylea

Regeneron

Preclinical

5 3

Emend IV

PORTRAZZA

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

1 6

Ketalar

AAultman Health Foundation

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 9

Andriol

AAuxilium

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2032

Phase 3Not yet recruiting

Colorectal Cancer

NCT06446557

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer

Not yet recruiting·UUniversity Hospital, Rouen·Phase 3·NCT06446557·408 enrolled

Pneumonia1 trial

Antimicrobial Stewardship For Ventilator Associated Pneumonia in Intensive Care

Recruiting·AAssistance Publique - Hôpitaux de Paris·N/A·NCT05124977·590 enrolled

Digestive Cancer1 trial

Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer

Completed·UUniversity Hospital, Rouen·Phase 3·NCT02956876·207 enrolled

Back pain1 trial

Assessing the Effects of HbA1c Reduction on Alleviating Nonspecific Back Pain

Completed·UUniversity of Baghdad·N/A·NCT06064058·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for standard management. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — standard management compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for standard management. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Rouen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Rouen

standard management

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2032

Trials by Indication[1]

Colorectal Cancer1 trial

Pneumonia1 trial

Digestive Cancer1 trial

Back pain1 trial

References

Drug Info

Quick Facts

Related News